Published in Cancer Weekly, October 11th, 2005
The transaction provides MedImmune with three preclinical stage programs developing monoclonal antibodies (MAbs) that target the B-cell antigens CD19, CD20 and CD22. These antigens are believed to play important roles in regulating the immune system.
Under the terms of the agreement, MedImmune will acquire all outstanding equity interests of Cellective in a cash transaction that is subject to necessary government approval. MedImmune will also provide Cellective...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.